RxDoctor Payments Data

Lori Claycomb

Family · Johnstown, PANPI 1023779527

Payments from drug & device makers

$1,500in general payments, 2019–2025

Across 86 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$241
  • Novo Nordisk$224
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$209
  • Exact Sciences$166
  • Gilead$163
  • Corcept Therapeutics$106
  • plus $391 from 12 others

What the payments were for

  • Food & beverage$1,500100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,500 in reported general payments places this provider in the 75th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$1,499
Medicare patients
33
Services billed
63

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban150$94,929
FarxigaDapagliflozin Propanediol110$77,377
TrulicityDulaglutide55$53,455
OzempicSemaglutide40$38,550
JardianceEmpagliflozin55$33,475
JanuviaSitagliptin Phosphate53$29,513
EntrestoSacubitril/Valsartan23$20,835
TradjentaLinagliptin39$20,551
XareltoRivaroxaban24$12,870
Tresiba Flextouch U-200Insulin Degludec14$11,137
MyrbetriqMirabegron26$10,752
TrintellixVortioxetine Hydrobromide17$7,410
Atrovent HfaIpratropium Bromide11$6,964
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$6,192
Incruse ElliptaUmeclidinium Bromide11$3,327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$28$94,929150 claims
AstraZenecaFarxiga, Symbicort$18$79,716121 claims
Lilly USA, LLCTrulicity$58$53,45555 claims
Novo NordiskOzempic, Levemir$224$40,70551 claims
NovartisEntresto$12$20,83523 claims
Astellas Pharma US IncMyrbetriq$55$10,75226 claims
GSKIncruse Ellipta$67$3,32711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,717 family providers in Pennsylvania.

Other family in Johnstown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →